

RESEARCH ARTICLE

Drug–drug interactions in pediatric oncology patients

T. E. Balk^{1,2} | I. H. van der Sijs¹ | T. van Gelder¹ | J. J. B. Janssen³ | I. M. van der Sluis⁴ | R. W. F. van Leeuwen^{1,3} | F. K. Engels¹

¹Department of Pharmacy, Erasmus MC, Rotterdam, The Netherlands

²Faculty of Pharmacy, Utrecht University, Utrecht, The Netherlands

³Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

⁴Department of Pediatric Hematology-Oncology, Erasmus MC-Sophia, Rotterdam, The Netherlands

Correspondence

F. K. Engels, Department of Pharmacy, Erasmus MC, Postbus 2040, 3000 CA Rotterdam, The Netherlands.

Email: f.engels@erasmusmc.nl

Abstract

Background: Drug–drug interactions (DDIs) can negatively affect pharmacotherapy. However, pediatric DDI studies are scarce. We undertook an exploratory study to investigate prevalence and clinical relevance of DDIs between cytostatic and noncytostatic drugs in outpatient pediatric oncology patients.

Procedure: After informed consent and inclusion, the following information was collected: currently prescribed noncytostatic and cytostatic drugs, comorbidities, and use of over-the-counter (OTC) drugs, complementary and alternative medicines (CAMs), and dietary supplements. All medication was screened for DDIs according to two databases: Micromedex[®] Solutions and the Dutch drug database G-Standard. The researcher presented DDIs with an associated potential for adverse outcome and a proposal for intervention to three independent experts. If the experts considered a DDI to be potentially clinically relevant and requiring intervention, the physician was notified.

Results: Seventy-three patients were included (median age 8.9 years). A total of 67 different DDIs were counted (66 in Micromedex[®] Solutions, 14 in G-Standard, and 13 DDIs in both databases). The medication reviews resulted in 35 interventions related to 11 different DDIs. The majority of DDIs concerned noncytostatic drugs (25/35) and one third occurred between cytostatic and noncytostatic drugs (10/35). The use of QTc-interval-prolonging drugs resulted in one intervention. The use of OTC drugs, CAM, or dietary supplements did not lead to DDIs.

Conclusions: This study resulted in a selection of 11 potentially clinically relevant DDIs for 73 outpatients in our pediatric oncology department. Interventions were formulated in close collaboration between physicians and clinical pharmacists. Future research should focus on assessing DDIs concerning QTc-interval prolongation.

KEYWORDS

cancer pharmacology, chemotherapy, drug–drug interactions, pediatric hematology/oncology, support care

1 | INTRODUCTION

The pharmacotherapeutic treatment of cancer patients is often associated with multiple side effects. In addition, a combination of drugs may result in drug–drug interactions (DDIs), which can adversely impact drug/treatment efficacy and lead to (serious) side effects or even life-threatening events.¹ Of all adverse reactions related to pharmacotherapy in adults, it is estimated that 20–30% are DDIs.¹ Moreover, the risk of a DDI due to the concomitant use of two drugs

is approximately 6%, and this risk increases exponentially with the increase in the number of prescribed drugs.²

In our hospital, cytostatic drugs are electronically prescribed in a prescribing system different from, and not linked to, the prescribing system used for noncytostatic drugs. As a result, there is no automatic check for DDIs between these drugs and consequently there is no DDI alert for the prescriber. The majority of research on DDIs has been conducted in adult oncology patients,^{3–8} and pediatric DDI research in this area is scarce.⁹ It is possible that pediatric patients react differently from adults to drugs or to drug combinations, which (in part) could be explained for by age-related developmental differences in body composition and organ function, thus affecting drug

Abbreviations: ALL, acute lymphoblastic leukemia; DDI, drug–drug interaction; MTX, methotrexate; OTC, over-the-counter; SSD, selective decontamination of the digestive tract

pharmacokinetics (PK), pharmacodynamics (PD), or both.¹⁰ We, therefore, undertook an exploratory, prospective study to investigate the prevalence and clinical relevance of DDIs between cytostatic and non-cytostatic drugs (including over-the-counter [OTC] drugs, complementary and alternative medicines [CAMs], and dietary supplements) in outpatient pediatric oncology patients.

2 | METHODS

A prospective, observational, and descriptive study was performed during a 4-month period (November 2014 to February 2015) at the Department of Pediatric Hematology-Oncology of Erasmus MC-Sophia. Patients were randomly approached without regard to diagnosis, planned treatment schedule, or responsible physician. After informed consent and inclusion, the following information was collected: list of currently prescribed noncytostatic drugs (from community pharmacy and hospital prescribing system) and prescribed cytostatic drugs for the next 3 months (from hospital oncology prescribing system). Through a structured oral interview, the medication overviews were verified and specific patient-related information, such as comorbidities and use of OTC drugs, CAM, and dietary supplements, was obtained.

The study population consisted of outpatients younger than 18 years treated with cytostatic drugs at the pediatric oncology ward of an academic children's hospital, Erasmus MC-Sophia in Rotterdam. The outpatient setting was selected because this is a population at risk for incomplete medication overviews,⁴ thus limiting a complete medication review by the pharmacy. Patients were included after obtaining written informed consent from both parents or guardians and from the patients who were older than 12 years. Patients were excluded in case of insufficient knowledge of the Dutch or English language and if it was not possible to obtain a list of currently prescribed drugs or to conduct a structured oral interview.

Micromedex[®] Solutions and the Dutch drug database G-Standard^{11,12} were used to screen and assess DDIs as such making use of both international and national databases. Additional information required to optimally assess potential DDIs was extracted from the hospital information system. The per-patient DDIs, and when applicable proposed interventions, were presented to a committee of three independent experts (hospital pharmacist, internist-clinical pharmacologist, resident in internal medicine) by the researcher. Feedback from each expert was independently submitted back to the researcher. If there was inconsistency in the feedback, the independent experts were asked to reach a consensus, upon which the identified DDI requiring an intervention was considered to be clinically relevant. The (hemato)oncologist in charge of the patient was advised how to manage this DDI.

3 | RESULTS

During the study period, a total of 83 patients were randomly approached of which 73 were included (88%). Ten patients declined

TABLE 1 Patient characteristics

Variable	Patients (n = 73)	
Age (years)		
Median (range)	8.9	(0.5–17.5)
Sex		
Male	42	58%
Female	31	
Type of malignancy		
<i>Solid tumors</i>		
Brain tumors		
-Low-grade glioma	3	4%
-High-grade glioma	1	1%
-Medulloblastoma	7	10%
Other		
-Neuroblastoma	4	5%
-Hepatoblastoma	1	1%
-Nephroblastoma	2	3%
-Rhabdomyosarcoma	7	10%
-Ewing sarcoma	2	3%
<i>Hematological tumors</i>		
ALL	39	53%
AML	1	1%
HL	3	4%
NHL	3	4%

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.

participation, mostly because they already participated in other studies. All patients included were treated with a curative intent. The main patient characteristics are summarized in Table 1.

3.1 | Potential DDIs

Based on Micromedex[®] Solutions and the G-Standard database, a total of 67 different DDIs were identified; 66 DDIs were documented in Micromedex[®] Solutions, 14 DDIs were found in the G-Standard database, and 13 DDIs were found in both databases. The DDIs of all patients summed up to a total of 432 (359 in Micromedex[®] Solutions, 73 in the G-Standard database; Table 2), with a median of five DDIs per patient (range 0–28). Our patients used a median of five drugs (range 2–16) concomitant to the (standard) drugs prescribed in the cytostatic treatment course and concomitant to any OTC drugs, CAM, or dietary supplements. In our study, 83.5% of the patients were exposed to at least one DDI. The majority of DDIs were classified in the category “major severity,” which we could attribute to the interaction between cotrimoxazole and methotrexate (MTX), dose unspecified. However, as discussed further, only high- and intermediate-dose MTX required an intervention. Of note, 84 QTc-interval-prolonging interactions were counted by Micromedex[®] Solutions, whereas the G-Standard database counted none. An overview of the QTc-interval-prolonging drugs prescribed in our population is shown in Table 3.

TABLE 2 Classification of levels of severity in Micromedex Solutions[®] and G-Standard database

Micromedex [®] Solutions			
Level of severity	DDIs (n)	DDIs (%)	Description
Minor	11	3.1	The DDI would have limited clinical effects. Manifestations may include an increase in the frequency or severity of the side effects but generally would not require a major alteration therapy
Moderate	96	26.7	The DDI may result in exacerbation of the patient's condition and/or require an alteration therapy
Major	252	70.2	The DDI may be life-threatening and/or require medical intervention to minimize or prevent serious adverse effects
Contraindicated	0	0	The drugs are contraindicated for concurrent use
Unknown	0	0	Unknown
Total	359	100%	
G-Standard database			
Level of severity	DDIs (n)	DDIs (%)	Description
A	2	3.0	Clinically insignificant or no effect
B	0	0	Short-term discomfort (<24 to 48 hr) without sequelae
C	6	9.1	Long-term discomfort (48–168 hr) without sequelae
D	4	6.1	Long-term (>168 hr), permanent sequelae, invalidity
E	8	1.5	Failure of lifesaving therapy, QTc-interval prolongation, rhabdomyolysis, vincristine toxicity, lung toxicity, etc.
F	53	80.3	Torsade de pointes, ventricular tachycardia, death, etc.
Total	73	100%	

TABLE 3 QTc-interval-prolonging drugs in the studied population

Known risk	Possible risk	Conditional risk
Azithromycin	Crizotinib	Amitriptyline
Ciprofloxacin	Dasatinib	Itraconazole
Fluconazole	Granisetron	Voriconazole
Ondansetron		

Classification according to CredibleMeds[®] Database.³³

3.2 | Interventions

The medication reviews resulted in 35 interventions on 11 different DDIs (Table 4). Most interventions concerned interactions between noncytostatic drugs (25 out of 35) and 10 interventions were related to an interaction between a cytostatic and a noncytostatic drug.¹³

DDIs needing interventions mainly concerned the following (number of interventions in parenthesis): prophylactic oral ciprofloxacin in combination with magnesium gluconate (1), levothyroxin (1), dexamethasone (10), or prednisolone (13); MTX (high/intermediate dose) in combination with pneumocystis pneumonia prophylactic cotrimoxazole (2); vincristine in combination with itraconazole (2), voriconazole (1), aprepitant (3), or filgrastim (1); and a combination of three QTc-interval-prolonging drugs: azithromycin, granisetron, and crizotinib (1).

3.3 | OTC drugs, CAM, dietary supplements

In our study, patients used a median of 1.9 OTC drugs (range 0–8). The following OTC drugs, CAM, and dietary supplements were found (number of patients in parenthesis): acetaminophen (68), mul-

tivitamins (13), vitamin D (9), melatonin (5), fishoil (2), magnesium (1), and others (45). In the Netherlands, the use of vitamin D supplements is advised for children under 4 years old,¹⁴ which explains the majority of the users in the study population (seven out of nine patients). No DDIs were found with OTC medication, CAM, or dietary supplements.

One patient used cannabidiol oil for pain relief and for anti-emetic reasons. However, this was not dispensed upon a prescription complying with the Dutch Opium Act, but purchased through an illegal distributor. Since 2001, the Office of Medicinal Cannabis (OMC) is the Dutch government agency responsible for the production and distribution of legal cannabis for medical purposes. There is currently one pharmacy in the Netherlands that prepares and dispenses medicinal cannabis oil from the medicinal cannabis of the OMC. All other cannabis, in whatever form, is illegal in the Netherlands.

4 | DISCUSSION

To our knowledge, this study is the first to assess the prevalence of clinically relevant DDIs among outpatient pediatric cancer patients in combination with specific interventions and advice on how to manage the determined DDI. The majority of DDIs concerned noncytostatic drugs (25/35) and one third occurred between cytostatic and noncytostatic drugs (10/35). The use of OTC medication, CAM, or dietary supplements was low and did not lead to DDIs. Close collaboration between physicians, clinical pharmacologists, and pharmacists resulted in a well-defined selection of 11 clinically relevant DDIs. There are several reasons why we strongly advise this collaboration to be continued, also outside the setting of a clinical trial; in

TABLE 4 Interventions on DDIs

Drug (victim)	Route	Drug (perpetrator)	Route	N	PK/PD	Effect DDI	Intervention	Intervention according to Hansten and Horn ¹³	Severity/documentation	
									Micromedex [®] Solutions	G-Standard ^a
Ciprofloxacin	p.o.	Magnesium gluconate	p.o.	1	PK	20–80% decreased ciprofloxacin	Interval schedule; administer ciprofloxacin at least 4 hr before magnesium	Interval schedule, monitor response	Moderate, good	C3
Levothyroxin	p.o.	Ciprofloxacin	p.o.	1	PK	39% decreased AUC of levothyroxine	Interval schedule; administer ciprofloxacin 2 hr after levothyroxine	Interval schedule (6 hr) and monitor	Moderate, good	N/A
MTX (HD)	i.v.	Co-trimoxazole	All	1	PK	Increased risk of MTX toxicity	Stop co-trimoxazole 48 hr before and 7 days after the MTX infusion	Choose other antibiotic treatment	Major, excellent	F3
MTX (intermediate)	i.v.	Co-trimoxazole	All	1	PK				Major, excellent	F3
Vincristine	i.v.	Itraconazole	All	2	PK	Increased vincristine plasma levels due to CYP3A inhibition	Vincristine q3wk: stop azole 3 days in advance till 1 day after Vincristine qwk: stop azole if possible or change to fluconazole and monitor side effects	Consider other antifungal treatment	Major, excellent	E2
Vincristine	i.v.	Voriconazole	All	1	PK			Consider other antifungal treatment	Major, good	E2
Vincristine	i.v.	Aprepitant	p.o.	3	PK	Increased vincristine plasma levels due to CYP3A inhibition	Monitor side effects	N/A	Major, fair	N/A
Ciprofloxacin	All	Dexamethasone	All	10	PD	Increased risk for muscle pain and tendon rupture	Monitor side effects	Monitor side effects	Moderate, excellent	N/A
Ciprofloxacin	All	Prednisolone	All	13	PD		Monitor side effects	N/A	Moderate, excellent	N/A
Vincristine	i.v.	Filgrastim	i.v.	1	PD	Severe peripheral neuropathy	Monitor side effects	N/A	Major, good	N/A
Concomitant use of granisetron, crizotinib, azitromycin	All	-	All	1	PD	Increased risk of QTc-interval prolongation	Stop medication if possible or monitor ECG	N/A	Major, fair	N/A

^a Level of documentation G-Standard: 2, well documented and published case reports; 3, controlled published interaction studies in patients/volunteers on relevant surrogate endpoints. For interpretation of letters (i.e., severity G-Standard); see Table 2.

N, number of interventions; N/A, this DDI is not found in the database. ECG, electrocardiography; HD, high dose; MTX, methotrexate; PK/PD, pharmacokinetic/pharmacodynamic interaction.

many hospitals, there is (still) no automatic/electronic drug interaction alert between cytostatic and noncytostatic drugs and as such prescribers must rely on DDI references and their proposed interventions, which are often inconsistent. In addition, close interdisciplinary collaboration also increases the awareness for potentially clinically relevant DDIs and may help to reduce alert fatigue, an important issue in DDI clinical decision support.¹⁵ We anticipate several issues that can impact the occurrence of DDIs in pediatric oncology such as an increase in the use of tyrosine-kinase inhibitors, known to result in clinically relevant DDIs,¹⁶ and more use of CAMs, also known to be involved in PK/PD interactions with chemotherapeutics,¹⁷ yet freely available via the Internet and often of inferior pharmaceutical quality. The approach of our study has several strengths. There were no restrictions based on tumor type regarding inclusion of patients, which resulted in a varied, yet representative population. Furthermore, we used a national (G-Standard) and an international (Micromedex[®] Solutions) DDI database, both widely used in clinical practice. A limitation of this study is that patients were not followed over time to monitor the outcome of the proposed interventions.

Several of the DDIs we found require a short discussion here. The combination of cotrimoxazole and MTX results in increased MTX toxicity involving reduced folate metabolism, synergistic nephrotoxicity, and reduced MTX clearance.¹⁸ Indeed, Micromedex[®] Solutions and G-Standard both classify this DDI as “major” and advise to avoid the combination of MTX (dose unspecified) and cotrimoxazole. This explains the high rate of major DDIs found in our study (Table 2). However, we only proposed an intervention for high-dose MTX (defined as ≥ 500 mg/m²) and intermediate-dose MTX (defined as 200–500 mg/m²); cotrimoxazole was discontinued from 48 hr prior to 7 days after MTX infusion according to the Dutch Childhood Oncology Group (DCOG) supportive care guidelines.¹⁹ The majority of cases classified as “major” DDI required no intervention, as the MTX dose was low or the cotrimoxazole already discontinued. Interestingly, recent research found no evidence for an interaction between high-dose MTX (2.5 or 5 g/m²) and prophylactic cotrimoxazole.²⁰ Notably, Brandalise et al.²¹ implemented the same precautions (leucovorin, hydration, and alkalization) for 3-weekly MTX 200 mg/m² MTX as for HD-MTX. Given the most recent data from Watts et al.,²⁰ our current advice may require a revision.

Ciprofloxacin is used for prophylaxis of bacterial infections during neutropenia,^{19,22} sometimes referred to as selective decontamination of the digestive tract, SDD (although ciprofloxacin is also absorbed into the systemic circulation). Magnesium salts cause a decrease in ciprofloxacin absorption by 20–80% due to chelation in the gut lumen, and the same occurs with calcium salts, although to a lesser extent.²³ An intake schedule in which ciprofloxacin is administered at least 4 hr before a magnesium salt intake is routinely advised.^{11,23} Interestingly, the DCOG guidelines do not advise an interval for co-administration with milk products or tube feeds stating that ciprofloxacin is used prophylactically and that tube feeds are often already stopped for other, more compelling reasons, making it difficult to achieve the target intake per day.¹⁹ However, the most important reason is that clinical experience has demonstrated that rectal SDD swabs are negative,

implying that the amount of ciprofloxacin available in the gut lumen is still sufficient despite the chelation interaction.

In adults, the use of ciprofloxacin can cause pain around an affected tendon or lead to a complete tendon rupture. Corticosteroids may potentiate this side effect.²⁴ In our study, approximately one third of the patients (23/73) were prescribed a combination of ciprofloxacin with either prednisolone or dexamethasone. Although no pediatric research has been performed and tendinopathy is mostly reported in middle-aged individuals, the DDI was reported to the responsible hemato-oncologist given the severity of the outcome.²⁵

In the case of the DDI between vincristine and azole antifungals, it is advised to avoid concomitant use by stopping the azole temporarily to prevent peripheral neuropathy,^{26,27} although there is no consensus about the length of this azole-free period.^{19,28} This is an issue that requires further research.

The interaction between vincristine and aprepitant is based on moderate CYP3A4 inhibition by aprepitant.²⁹ Since this DDI could have severe implications, the review committee advised to monitor neurotoxicity. Vincristine is associated with minimal emetic risk³⁰; therefore, aprepitant is always initiated to mitigate the emetogenic potential of another cytostatic drug in the treatment schedule. In children already experiencing vincristine-induced neurotoxicity, one could consider administering vincristine 48 hr later, thereby preventing the DDI. We anticipate an increase in pediatric aprepitant use now that the suspension have become available and physicians should be aware of this DDI.³¹

In our study, two patients who used several QTc-interval-prolonging drugs³² required a more detailed review. The G-Standard database advises to avoid administration of two or more drugs from the list “Drugs with known Torsade de Pointes (TdP) risk” by CredibleMeds[®]³³; if concomitant use is unavoidable, the physician should monitor the ECG.³³ Micromedex[®] Solutions gives a similar advice but does not classify QTc-interval-prolonging drugs in risk categories, which explains the difference in found DDIs (84 QTc-interval-prolonging DDIs in Micromedex[®] Solutions vs. 0 in G-Standard database). In the first patient, five different QTc-interval-prolonging drugs were prescribed: two drugs with “Known risk of TdP,” two with “Possible risk of TdP,” and one with “Conditional risk of TdP” (Table 4). As one of the two “Known risk of TdP” drugs was prescribed as “on demand,” this DDI was assessed to be not clinically relevant and no intervention was proposed.³³ The second patient was prescribed three QTc-interval-prolonging drugs of which one is on the list “Known risk of TdP” and two on the list “Possible risk of TdP.” There are currently no guidelines that propose interventions upon administration of a combination of QTc-interval-prolonging drugs from different lists of CredibleMeds[®]. However, given the severity of the possible side effect, we advised to monitor the ECG in the case of one “Known risk of TdP” and two “Possible risk of TdP” drugs (excluding “as needed” drugs). It is important to note that this intervention has not been validated and requires further research.

One intervention describes the concurrent use of vincristine and filgrastim, which has been associated with an increase in peripheral neuropathy.³⁴ A higher cumulative vincristine dose could increase the

chance of neurotoxicity. Since the consequences can be serious, physicians were informed.

Research on the use of OTC drugs in the pediatric oncology population is scarce.³⁵ However, research in adults showed that 80% of the patients use OTC drugs, which in 10% of the cases results in a DDI.⁴ In our study, the use of OTC drugs, CAM, and dietary supplements did not result in DDIs, possibly due to the proactive policy the physicians pursue concerning those drugs: patients are strongly advised not to use any medication other than the anti-cancer treatment without first consulting their physician.

In conclusion, this study gives insight into the prevalence and clinical relevance of DDIs in this specific population. Research on DDIs in the pediatric population is limited and most studies have small study populations. We strongly advise hemato-oncologists, clinical pharmacologists, and pharmacists to collaborate in identifying and managing the discussed DDIs. Currently, there is no clear guideline on assessing DDIs concerning multiple QTc-interval-prolonging drugs. This subject should be a focus of future research.

ACKNOWLEDGMENTS

We would like to thank all participating hemato-oncologists, research nurses, and oncology nurses at the Erasmus MC-Sophia Children's Hospital Rotterdam.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

- Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug–drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. *Int J Clin Pharmacol Ther*. 2000;38(11):504–513.
- Kuhlmann J, Muck W. Clinical–pharmacological strategies to assess drug interaction potential during drug development. *Drug Saf*. 2001;24(10):715–725.
- Van Leeuwen RWF, Brundel DH, Neef C, et al. Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs. *Br J Cancer*. 2013;108(5):1071–1078.
- Van Leeuwen RWF, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. *Ann Oncol*. 2011;22(10):2334–2341.
- Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug–drug interactions between anti-cancer agents and community pharmacy dispensed drugs. *Pharm World Sci*. 2010;32(5):575–580.
- Hadjibabaie M, Badri S, Ataei S, Moslehi AH, Karimzadeh I, Ghavamzadeh A. Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study. *Cancer Chemother Pharmacol*. 2013;71(6):1619–1627.
- Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. *J Natl Cancer Inst*. 2007;99(8):592–600.
- Van Leeuwen RW, Jansman FG, van den Bemt PM, et al. Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions. *Ann Oncol*. 2015;26(5):992–997.
- Fernandez de Palencia Espinosa MA, Diaz Carrasco MS, Fuster Soler JL, Ruiz Merino G, De la Rubia Nieto MA, Espuny Miro A. Pharmacoepidemiological study of drug–drug interactions in onco-hematological pediatric patients. *Int J Clin Pharm*. 2014;36(6):1160–1169.
- Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. *N Engl J Med*. 2003;349(12):1157–1167.
- Dutch Pharmacists Association (KNMP). *Dutch Drug Database G-standard*. <https://kennisbank.knmp.nl/>. Accessed July 22, 2015.
- Truven Health. *Micromedex Solutions*. <http://www.micromedex.com/home/dispatch/CS>. Accessed July 22, 2015.
- Hansten PDA, Horn JRA. *Drug Interactions Analysis and Management*. 2009 revised ed. Vancouver; Facts & Comparisons Publishing Group 2009.
- Health Council of the Netherlands. Evaluation of Dietary Reference Values for Vitamin D. 2012. <http://www.gezondheidsraad.nl/sites/default/files/201215EEvaluationDietaryReferenceVitaminD.pdf>.
- Payne TH, Hines LE, Chan RC, et al. Recommendations to improve the usability of drug–drug interaction clinical decision support alerts. *J Am Med Inform Assoc*. 2015;22(6):1243–1250.
- Van Leeuwen RWF, Van Gelder T, Mathijssen RH, Jansman FG. Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. *Lancet Oncol*. 2014;15(8):e315–e326.
- Yap KY, See CS, Chan A. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. *Recent Pat Food Nutr Agric*. 2010;2(1):12–55.
- Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole: toxicity from this combination continues to occur. *Can Fam Phys*. 2014;60(1):53–56.
- Dutch Childhood Oncology Group (SKION). *Infection Prevention*. 2015. <https://www.skion.nl/workspace/uploads/H4-SP-Infectiepreventie-mei-2015.pdf>. Accessed September 12, 2015.
- Watts CS, Sciasci JN, Pauley JL, et al. Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate. *J Pediatr Hematol/Oncol*. 2016;38(6):449–452.
- Brandalise SR, Pinheiro VR, Aguiar SS, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group—protocol ALL-99. *J Clin Oncol*. 2010;28(11):1911–1918.
- Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. *Cochrane Database Syst Rev*. 2012;1:CD004386.
- Baxter K, Stockley IH. *Stockley's Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance, and Management*. 8th ed. London; Chicago: Pharmaceutical Press; 2008.
- Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon injury and fluoroquinolone use: a systematic review. *Drug Saf*. 2013;36(9):709–721.
- Mullen CA, Nair J, Sandesh S, Chan KW. Fever and neutropenia in pediatric hematopoietic stem cell transplant patients. *Bone Marrow Transplant*. 2000;25(1):59–65.
- Lam MSH, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. *J Oncol Pharm Pract*. 2003;9(2–3):45–85.
- Haidar C, Jeha S. Drug interactions in childhood cancer. *Lancet Oncol*. 2011;12(1):92–99.

28. Pana ZD, Roilides E. Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem, new dilemma. *Pediatr Blood Cancer*. 2011;57(1):30–35.
29. Aapro MS, Walko CM. Aprepitant: drug–drug interactions in perspective. *Ann Oncol*. 2010;21(12):2316–2323.
30. Dupuis LL, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. *Pediatr Blood Cancer*. 2011;57(2):191–198.
31. Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2015;16(4):385–394.
32. Roden DM. Drug-induced prolongation of the QT interval. *N Engl J Med*. 2004;350(10):1013–1022.
33. Woosley RL, Romero KA. Drug lists by risk groups: drugs that prolong the QT interval and/or induce Torsades de Pointes. In: *CredibleMeds QTdrugs List*. <https://www.crediblemeds.org/new-drug-list/>. Accessed July 22, 2015.
34. Weintraub M, Adde MA, Venzon DJ, et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. *J Clin Oncol*. 1996;14(3):935–940.
35. Magi T, Kuehni CE, Torchetti L, Wengenroth L, Luer S, Frei-Erb M. Use of complementary and alternative medicine in children with cancer: a study at a Swiss University Hospital. *PLoS ONE*. 2015;10(12):e0145787.

How to cite this article: Balk TE, van der Sijs IH, van Gelder T, Janssen JJB, van der Sluis IM, van Leeuwen RWF, and Engels FK. Drug-drug interactions in pediatric oncology patients. *Pediatr Blood Cancer*. 2017;e26410. doi:10.1002/pbc.26410.